PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 2,700 shares, a decrease of 70.7% from the February 28th total of 9,200 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 26,300 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

A number of research firms recently issued reports on PYPD. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw started coverage on PolyPid in a report on Tuesday, January 28th. They set a “buy” rating and a $13.00 price target for the company. Finally, HC Wainwright dropped their target price on PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, December 26th.

PolyPid Price Performance

PYPD traded up $0.02 on Friday, hitting $2.74. 32,315 shares of the stock were exchanged, compared to its average volume of 13,648. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. PolyPid has a 12 month low of $2.37 and a 12 month high of $5.09. The firm has a market capitalization of $27.92 million, a price-to-earnings ratio of -0.55 and a beta of 1.27. The business has a 50-day moving average of $2.97 and a two-hundred day moving average of $3.18.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). Sell-side analysts forecast that PolyPid will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Rosalind Advisors Inc. grew its position in PolyPid by 50.6% during the 4th quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock worth $3,108,000 after acquiring an additional 343,353 shares during the last quarter. AIGH Capital Management LLC increased its stake in shares of PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after buying an additional 148,199 shares during the period. Stonepine Capital Management LLC bought a new position in PolyPid in the 3rd quarter valued at approximately $476,000. Finally, J. Goldman & Co LP acquired a new stake in PolyPid during the 4th quarter worth approximately $391,000. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.